ClinicalTrials.gg
RecruitingNCT07514936Updated Aug 20, 2026

Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

A Phase 3 interventional study of the standard "3+7" regimen and Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte in Newly Diagnosed Acute Myeloid Leukemia (AML) and Elderly Patients, sponsored by Chinese PLA General Hospital. Recruiting at 1 site in China. Open to participants aged 60 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Chinese PLA General Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Nov 2024, registered Nov 2025).
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
60 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.

Planned enrollment
54th of 211
120 · median 50
Started
2024
with 21 others
Phase 3
26 of 214
7 open now
Primary completion
2027-09
later than 38 of 90 live
Registered
192nd of 214
by date
Lead sponsor
4 of 214
Chinese PLA General Hospital

Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 54th largest by planned enrollment of the 211 interventional ones that give a count, is one of 22 that started in 2024, is one of 26 in phase 3, reaches primary completion later than 38 of the 90 other live ones, and was the 192nd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

67 more — sign in →

By country, each count listing its studies:

All 72 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 60 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing azacitidine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This study is a multicenter, prospective, randomized, controlled clinical trial, observing the efficacy and safety of the CACAG+Venetoclax regimen (Chidamide + Azacitidine + Aclarubicin + Cytarabine + Recombinant Human Granulocyte Colony-Stimulating Factor + Venetoclax) in elderly patients with newly diagnosed Acute Myeloid Leukemia (AML). The control group applies the standard "3+7" regimen. The aim is to improve the remission rate of AML patients, reduce the probability of adverse events, and thereby improve patient prognosis and extend patient survival.

03

Conditions studied

  • Newly Diagnosed Acute Myeloid Leukemia (AML)
  • Elderly Patients

Keywords

  • Elderly Patients
  • newly diagnosed
  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
60 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in the clinical study; the subject or legal guardian fully understands and is informed about the study and has signed the Form (ICF); willing to follow and able to complete all trial procedures;
  2. Age between 60-75 years at the time of screening, with no gender restrictions;
  3. Patients are newly diagnosed with AML, and the diagnosis conforms to the standards of the Chinese Medical Association 2021 edition;
  4. No severe allergic constitution;
  5. Liver function: and AST \<= 2.5 times the values, \<= 2 times the upper limit of normal values;
  6. Renal function: creatinine \<= upper limit of normal values;
  7. No uncontrollable infections or severe mental illnesses;
  8. Performance status score is 0-3 (), with an expected survival of at least 4 months.

Exclusion criteria

Exclusion Criteria:

  1. Patients who are allergic to the study medication or have to it;
  2. Pregnant or breastfeeding women;
  3. Patients with active infections;
  4. Patients with long-term smoking or alcohol abuse that could affect the evaluation of trial results;
  5. Patients with mental disorders or other conditions that prevent obtaining , or who are unable to cooperate with the treatment and examination procedures;
  6. Patients who have undergone major organ surgery within the last 6 weeks;
  7. Abnormal liver function, with total > 1.5 times the , /AST > 2.5 times the upper limit of normal, or liver-infiltrated patients with ALT/AST > 5 times the upper limit of normal; abnormal renal function, with serum creatinine > 1.5 times the upper limit of normal;
  8. Patients whom the investigator deems unsuitable for this clinical trial (e.g., poor compliance, drug abuse, etc.).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Venetoclax Combined With CACAG Regimen

    The entire treatment period for the CACAG+Venetoclax regimen in the trial is 2 week, with a treatment cycle of every 4 weeks, and a total of 2 course of treatment. Chidamide: 30 mg, twice a week, for a total of 4 administrations; Azacitidine: 75 mg/m\^2 from day 1 to day 7; Cytarabine (Ara-C): 75-100 mg/m\^2 every 12 hours from day 1 to day 7; Aclarubicin: 20 mg/m\^2 on days 1, 3, and 5; Recombinant human granulocyte colony-stimulating factor (G-CSF): 300 μg/day, to be discontinued when neutrophils recover and white blood cell count is ≥20,000/μL; Venetoclax: 100 mg on day 1, 200 mg on day 2, 400 mg from day 3 to day 14, used in combination with azoles, with a reduced dosage of 100 mg/day.

    Drug: Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte

  • Active comparator
    the standard "3+7" regimen

    IA Regimen: Idarubicin: 8-12 mg/m\^2 on days 1 to 3; Cytarabine (Ara-C): 100 mg/m\^2 every 12 hours on days 1 to 7. Or DA Regimen: Daunorubicin: 60 mg/m\^2 on days 1 to 3; Cytarabine (Ara-C): 100 mg/m\^2 every 12 hours on days 1 to 7. Or MA Regimen: Mitoxantrone: 6-10 mg/m\^2 on days 1 to 3; Cytarabine (Ara-C): 100 mg/m\^2 every 12 hours on days 1 to 7.

    Drug: the standard "3+7" regimen

Interventions

  • Drugthe standard "3+7" regimen

    IA Regimen: Idarubicin: 8-12 mg/m\^2 on days 1 to 3; Cytarabine (Ara-C): 100 mg/m\^2 every 12 hours on days 1 to 7. Or DA Regimen: Daunorubicin: 60 mg/m\^2 on days 1 to 3; Cytarabine (Ara-C): 100 mg/m\^2 every 12 hours on days 1 to 7. Or MA Regimen: Mitoxantrone: 6-10 mg/m\^2 on days 1 to 3; Cytarabine (Ara-C): 100 mg/m\^2 every 12 hours on days 1 to 7.

  • DrugAzacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte

    Drug pages: AzacitidineStudies of AzacitidineAzacitidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CytarabineStudies of CytarabineCytarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AclacinomycinsStudies of AclacinomycinsAclacinomycins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TucidinostatStudies of TucidinostatTucidinostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · VenetoclaxStudies of VenetoclaxVenetoclax pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GranulocyteStudies of GranulocyteGranulocyte pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    IA Regimen: Idarubicin: 8-12 mg/m\^2 on days 1 to 3; Cytarabine (Ara-C): 100 mg/m\^2 every 12 hours on days 1 to 7. Or DA Regimen: Daunorubicin: 60 mg/m\^2 on days 1 to 3; Cytarabine (Ara-C): 100 mg/m\^2 every 12 hours on days 1 to 7. Or MA Regimen: Mitoxantrone: 6-10 mg/m\^2 on days 1 to 3; Cytarabine (Ara-C): 100 mg/m\^2 every 12 hours on days 1 to 7.

06

What researchers measure

Primary outcomes

  1. Composite Complete Remission (CRc) Rate after 1 course of treatment

    a combination of complete remission (CR) and complete remission with incomplete blood count recovery (CRi)

    Time frame: 1 months after study treatment

Secondary outcomes

  1. Overall Response Rate (ORR) after 1 course of treatment

    Defined as the percentage of participants achieving a best overall response of complete response (CR), CR with incomplete blood count recovery (CRi), or partial response (PR).Biological characteristics exploratory studies were analyzed by single-cell sequencing and Atac-seq. Further, according to European LeukemiaNet risk group, we analyzed the outcomes of patients by molecular subtype as a sub-group analysis.

    Time frame: 1 months after the start of study treatment

  2. Complete Remission (CR) Rate after 1 courses of treatment

    Defined in accordance with the IWG Response Criteria in AML. Bone marrow blasts\<5 percent; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \>1.0 x 10\^9/L (1000/µL); platelet count \>100 x 109/L (100,000/µL); independence of red cell transfusions.

    Time frame: after 1 courses of chemotherapy (each course is 28 days)

  3. Rate of Minimal Residual Disease (MRD)-Negative Response

    Percentage of participants who achieved MRD-negative response, defined as \< 1 leukemia cell per 10,000 leukocytes as assessed by flow cytometry after each courses of chemotherapy (each course is 28 days)

    Time frame: after each courses of chemotherapy (each course is 28 days)

  4. Event-free survival

    Defined as the time interval from treatment initiation to the occurrence of induction failure,relapse,or death,whichever came first.

    Time frame: 180 days after study treatment

  5. Overall Survival

    Defined as the time from joining the clinical study to death due to any cause.

    Time frame: 180 days after study treatment

  6. Treatment-related adverse events

    Defined as adverse events that occurred from the first dose of study treatment to 30 days after the discontinuation of treatment.

    Time frame: From the first dose of study treatment to 30 days after the discontinuation of treatment

  7. Disease-free survival

    Defined as the time interval from disease remission to the occurrence of relapse or death,whichever came first.

    Time frame: 180 days after study treatment Outcome Measure

  8. Early death

    Defined as death within 30 days of chemotherapy.

    Time frame: Within 30 days of the start of the first course of treatment

  9. Complete Remission with Incomplete Blood Count Recovery (CRi)after 1 courses of treatment

    Disappearance of leukemia blasts in the bone marrow (\<5% blasts) but without full recovery of blood counts (neutrophils \<1.0 x 10⁹/L and/or platelets \<100 x 10⁹/L).

    Time frame: after 1 courses of chemotherapy (each course is 28 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Sep 2027, 34 months after the start.

Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's planned 34 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Apr 7, 2026
StartActual
Nov 18, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07514936
Collaborators
940 Hospital of the People's Liberation Army Joint Logistic Support Force, The General Hospital of Western Theater Command, First Affiliated Hospital of Harbin Medical University, 960th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Fourth Medical Center of PLA General Hospital, The First Medical Center of Chinese PLA General Hospital, The 306 Hospital of People's Liberation Army, Air Force General Hospital of the PLA
Responsible party
Daihong Liu (Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Chinese PLA General Hospital) — Principal investigator
First posted
Apr 7, 2026
Start date
Nov 18, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Dahong Liu Liu, doctor
Contact
daihongrmg@163.com
+8613681171597
Liping Dou, Doctor
Contact
lipingruirui@163.com
+8613681207138
Dahong Liu, Doctor
study chair · Chinese PLA General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · Cytarabine · Aclacinomycins · Tucidinostat · Venetoclax · Granulocyte

Start the discussion